STOCK TITAN
  1. Home
  2. Sec-filings
  3. MIRA
  4. [8-K] MIRA PHARMACEUTICALS, INC. Reports Material Event

Mira Pharmaceuticals (NASDAQ: MIRA) hires fractional CFO via LMAM

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Mira Pharmaceuticals is changing its finance leadership, with Chief Financial Officer Alan Weichselbaum ending his service effective June 6, 2026. The company states his departure is not due to any disagreement over operations, policies, or practices.

On June 2, 2026, the board appointed Andriy Mushak as fractional Chief Financial Officer, effective June 6, 2026. Mushak, a 43-year-old Certified Public Accountant with over 20 years of SEC reporting and audit experience, will provide services through LMAM Consulting Group, LLC under a consulting agreement, for which he will be paid $6,000 per month. The filing notes no relevant family relationships or related-party transactions requiring disclosure.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Effective CFO change date June 6, 2026 Date Alan Weichselbaum ceases serving as CFO and fractional CFO role begins
Appointment date June 2, 2026 Board appoints Andriy Mushak as fractional CFO
Fractional CFO monthly fee $6,000 per month Compensation to Andriy Mushak under Consulting Agreement
New CFO age 43 years Age of fractional Chief Financial Officer Andriy Mushak
Experience Over 20 years SEC reporting, accounting compliance, and audit experience of Andriy Mushak
fractional Chief Financial Officer financial
"appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026"
Consulting Agreement financial
"will be providing his services pursuant to the Consulting Agreement between the Company and LMAM"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 404(a) of Regulation S-K regulatory
"no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What executive change did MIRA announce in this 8-K filing?
Mira Pharmaceuticals reported that Chief Financial Officer Alan Weichselbaum will stop serving as CFO effective June 6, 2026. The company said his departure is not due to any disagreement over operations, policies, or practices, and it simultaneously appointed a fractional CFO.

Who is the new fractional CFO of MIRA and when is it effective?
The board appointed Andriy Mushak as Mira Pharmaceuticals’ fractional Chief Financial Officer effective June 6, 2026. He was appointed on June 2, 2026 and will provide CFO services while remaining employed by LMAM Consulting Group, LLC under a consulting arrangement.

How is MIRA compensating its new fractional CFO?
Mira Pharmaceuticals will pay Andriy Mushak $6,000 per month for his services as fractional Chief Financial Officer. The payments are made under a Consulting Agreement between the company and LMAM Consulting Group, LLC, through which Mushak will deliver his CFO services.

Does MIRA report any disagreements with the departing CFO?
The company states that Alan Weichselbaum’s departure as Chief Financial Officer was not the result of any disagreement with Mira Pharmaceuticals. This includes no disagreements regarding the company’s operations, policies, or practices, which can reassure investors about the nature of the transition.

What is LMAM’s role in MIRA’s CFO transition?
LMAM Consulting Group, LLC employs new fractional CFO Andriy Mushak and will provide his services to Mira Pharmaceuticals under a Consulting Agreement. LMAM specializes in SEC financial reporting, technical accounting, and M&A support, and Mushak will continue as a partner there while serving MIRA.
false 0001904286 0001904286 2026-06-02 2026-06-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 2, 2026

 

MIRA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Florida 001-41765   85-3354547
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

1200 Brickell Avenue, Suite 1950 #1183

Miami, Florida 33131

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (786) 432-9792

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, $0.0001 par value per share   MIRA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Andriy Mushak as the Fractional Chief Financial Officer

 

Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the “Company”). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. On June 2, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026 (the “Effective Date”).

 

Mr. Mushak, CPA, 43, is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting Group, LLC (“LMAM”), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in SEC financial reporting, technical accounting, and M&A transaction support. At LMAM, Mr. Mushak leads SEC reporting engagements, financial statement preparation, and advisory services for both publicly traded and privately held companies across diverse industries, including technology, life sciences, media, medical supplies, finance, and manufacturing. Prior to co-founding LMAM in 2025, Mr. Mushak served in the Audit practice at Baker Tilly US, LLP (Boston) for over a decade, most recently as a Senior Manager, where he led financial statement audits and provided assurance and advisory services for publicly traded and privately held clients. Mr. Mushak earned a Master of Science in Accounting and Auditing and a Bachelor of Arts in Economics from Buchach Institute of Management and Audit. Mr. Mushak is a Certified Public Accountant licensed by the Massachusetts Board of Public Accountancy.

 

Mr. Mushak has been, and will remain, employed by LMAM and will be providing his services pursuant to the Consulting Agreement between the Company and LMAM. The material terms of the engagement are that the Company will pay Mr. Mushak $6,000 per month for the services rendered by Mr. Mushak.

 

There are no family relationships, as defined in Item 401 of Regulation S-K, between Mr. Mushak and any of the Company’s executive officers or directors or persons nominated or chosen to become a director or executive officer.

 

Mr. Mushak has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

10.1   Consulting Agreement between MIRA Pharmaceuticals, Inc. and LMAM Consulting Group, LLC
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MIRA PHARMACEUTICALS, INC.
     
Dated: June 8, 2026 By: /s/ Erez Aminov
  Name: Erez Aminov
  Title: Chief Executive Officer

 

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

Other Documents